Qiagen Reports Restricted Stock Unit Grant to Board Member Metin Colpan

Qiagen ( (QGEN) ) has issued an announcement.

Qiagen has disclosed a manager transaction under EU market abuse regulations involving Metin Colpan, a member of its administrative or supervisory body. Colpan received a grant of 4,618 restricted stock units linked to Qiagen shares, allocated outside a trading venue on February 27, 2026, as part of a share-based incentive program.

The transaction is described as not quantifiable in terms of aggregated price or volume, underscoring that it is a non-cash, equity-based remuneration rather than an open-market trade. Such grants align management incentives with shareholder interests and signal Qiagen’s continued use of equity compensation to retain and motivate key leadership figures.

The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

More about Qiagen

Qiagen N.V. is a Netherlands-based life sciences company that develops and supplies sample and assay technologies for molecular diagnostics, applied testing, pharmaceuticals and academic research. Its shares are listed on multiple European exchanges as well as the NYSE and Swiss markets, reflecting a broad international investor base.

Average Trading Volume: 2,173,009

Technical Sentiment Signal: Strong Buy

Current Market Cap: $10.1B

For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.